We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aviat (AVNW) to Report Q3 Earnings: What's in the Cards?
Read MoreHide Full Article
Aviat Networks, Inc. (AVNW - Free Report) is set to report third-quarter fiscal 2021 results on May 5, after the closing bell. In the last reported quarter, the company delivered an earnings surprise of 62.6%. It pulled off a trailing four-quarter earnings surprise of 61.7%, on average.
This Austin, TX-based company is expected to have recorded higher revenues year over year. Its performance might have been driven by the increasing market traction of its microwave transport product and software offerings.
During the fiscal third quarter, Aviat was selected by DISH Network as a key supplier of 5G microwave transport. LTD Broadband, an Internet service provider, deployed Aviat’s WTM 4000 microwave and multi-band platform systems in its network middle mile for fiber redundancy.
For the March quarter, the Zacks Consensus Estimate for revenues is pegged at $64 million, indicating growth of 4.9% from the year-ago quarter’s reported figure. The consensus estimate for adjusted earnings per share is pegged at 37 cents, which suggests an increase of 85% year over year.
What Our Model Says
Our proven model doesn’t conclusively predict an earnings beat for Aviat this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Earnings ESP: Aviat’s Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is 0.00% as both are pegged at 37 cents.
Here are some companies that you may want to consider as our model shows that these have the right combination of elements to post an earnings beat this quarter:
GasLog Partners LP is scheduled to release first-quarter 2021 results on May 6. The company has an Earnings ESP of +7.25% and a Zacks Rank #1.
Welbilt, Inc. has an Earnings ESP of +92.31% and a Zacks Rank of 2. The company is set to report first-quarter 2021 results on May 6.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Aviat (AVNW) to Report Q3 Earnings: What's in the Cards?
Aviat Networks, Inc. (AVNW - Free Report) is set to report third-quarter fiscal 2021 results on May 5, after the closing bell. In the last reported quarter, the company delivered an earnings surprise of 62.6%. It pulled off a trailing four-quarter earnings surprise of 61.7%, on average.
This Austin, TX-based company is expected to have recorded higher revenues year over year. Its performance might have been driven by the increasing market traction of its microwave transport product and software offerings.
During the fiscal third quarter, Aviat was selected by DISH Network as a key supplier of 5G microwave transport. LTD Broadband, an Internet service provider, deployed Aviat’s WTM 4000 microwave and multi-band platform systems in its network middle mile for fiber redundancy.
For the March quarter, the Zacks Consensus Estimate for revenues is pegged at $64 million, indicating growth of 4.9% from the year-ago quarter’s reported figure. The consensus estimate for adjusted earnings per share is pegged at 37 cents, which suggests an increase of 85% year over year.
What Our Model Says
Our proven model doesn’t conclusively predict an earnings beat for Aviat this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Earnings ESP: Aviat’s Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is 0.00% as both are pegged at 37 cents.
Aviat Networks, Inc. Price and EPS Surprise
Aviat Networks, Inc. price-eps-surprise | Aviat Networks, Inc. Quote
Zacks Rank: Aviat currently has a Zacks Rank #3.
Stocks to Consider
Here are some companies that you may want to consider as our model shows that these have the right combination of elements to post an earnings beat this quarter:
Ironwood Pharmaceuticals, Inc. (IRWD - Free Report) is slated to release first-quarter 2021 results on May 6. It has an Earnings ESP of +14.94% and a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
GasLog Partners LP is scheduled to release first-quarter 2021 results on May 6. The company has an Earnings ESP of +7.25% and a Zacks Rank #1.
Welbilt, Inc. has an Earnings ESP of +92.31% and a Zacks Rank of 2. The company is set to report first-quarter 2021 results on May 6.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>